India Pharmaceuticals and Healthcare Report Q2 2008
Business Monitor International, March 2008, Pages: 101
The India Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Indias pharmaceuticals and healthcare industry.
BMI’s regional Business Environment Rankings table for Q2 208 once again ranks India as a moderately attractive proposition to multinational pharmaceutical companies operating in the Asia Pacific. Along with Malaysia, India is placed at a joint eighth position.. While its market size and annual growth indicators are viewed as some of the key attractions, India still suffers from the disadvantage of excessive red tape, an underdeveloped infrastructure, deficiency of legal framework, low per capita spending, and a large rural and poor population.
In addition, deficiencies in regulatory, intellectual property (IP) and pricing environments remain as barriers to investment. The Indian generic companies are defending themselves from costly patent litigation from a number of prominent multinationals, including Novartis and Roche. The latter, which filed a patent infringement suit against Cipla in January 2008, is in fact already involved in a patent suit with Ranbaxy Laboratories. On the other hand, a December 2007 decision by the Mumbai office to grant patent to Pfizer’s HIV/AIDS treatment Celzentry (maraviroc) represents a major turn-around in favour of the multinationals. While
Pfizer will be able to sell its product for treatment without the damaging effects of generic competition, revenues from the drug are not expected to be decisive for the company due to its high cost and the pathological tests required prior use. In the last decade, various Indian patent offices have turned down no less than 10 antiretroviral patent applications.
By 2012, the value of the India’s pharmaceutical market is expected to reach an impressive US$17.8bn mark, an increase from the current figure of US$12.2bn. Clearly, the market allows plenty of commercial opportunities. However, industry consolidation around a handful of large domestic players would squeeze smaller companies. Indeed, industry leaders, including Ranbaxy and Dr Reddys Laboratories, have continued to be active in early 2008. The latter launched a non-steroidal anti-inflammatory drug (NSAID) Supanac (diclofenac potassium). Supanac, in-licensed from Swiss Applied Pharma Research (APR), targets the US$688mn NSAID market, with two other leading NSAID brands produced by Dr Reddy’s, namely Nise (nimesulide) and Retoz (etoricoxib). Similarly, the domestic active pharmaceutical ingredient (API) industry is showing signs of expansion. In January 2008, Indian firm Dishman Pharmaceuticals and Chemicals reported its plan to build an API plant in China, in an effort to further penetrate the rapidly expanding contract research and manufacturing services (CRAMS) market. In the same month, Israeli generics giant Teva revealed its intention to strengthen its presence in Asia by specifically choosing India for API production. India, which already has over 200 good manufacturing practice (GMP) facilities, the highest number outside the US, is posing a strong challenge to China as the largest global API supplier.
Executive Summary
India Pharmaceutical Industry SWOT
India Political SWOT
India Economic SWOT
India Business Environment SWOT
India’s Pharmaceutical Business Environment Ratings
Table: Asia Pacific Pharmaceutical Business Environment Rankings For Q208
Limits Of Potential Returns
Risks To Realisation Of Returns
Market Summary
Regulatory Environment
Pharmacovigilance
Recent Regulatory Developments
IP Regime
Table: History Of The Indian Patent System
Deficiencies of IP Regime
Recent IP Developments
Patent Disputes
Counterfeit Medicines
Table: Anti-Counterfeiting Guidelines From The Organisation Of Pharmaceutical Producers Of India (OPPI)
Pricing And Reimbursement
Other Regulatory Developments
Industry Trends And Developments
Epidemiology
Healthcare Sector
Pharmaceutical Industry
Domestic Industry Developments
Foreign Company Developments
Retail Pharmacy Sector
Table: Major Players In Indias Retail Pharmacy Sector
Foreign Co-operation
Table: India - Asian FTA Situation
Clinical Research
Table: Clinical Trial Considerations In Asia
Active Pharmaceutical Ingredients
Table: APIs Manufactured By Hikal
Biotechnology Sector
Recent Biotechnology Sector Developments
Medical Devices
Industry Forecast Scenario
Overall Market Forecast
Table: Drug Expenditure and Prescription Market Indicators (US$mn unless otherwise staed)
Key Growth Factors - Industry
Table: India - Health Expenditure Forecasts
Key Growth Factors - Macroeconomic
Table: India - Economic Activity
Patented Market Forecast
Table: India Patented Forecasts (US$mn unless otherwise stated)
Generics Market Forecast
Table: India Generics And Branded Market Forecast Indicators
OTC Market Forecast
Table: India - OTC Market Forecasts (US$mn unless otherwise stated)
Export/Import Forecasts
Table: India Imports And Exports Forecasts (US$bn)
Other Healthcare Data Forecasts
Table: India Healthcare Data Forecasts
Key Risks To our Forecast Scenario
Competitive Landscape.56
Table: Ranking Of Indian Drug-makers By Retail Sales, July 2007
Company Profiles
Leading Multinational Manufacturers
- Pfizer
- GlaxoSmithKline (GSK)
- Novartis
- Sanofi-Aventis
- Merck & Co
- Eili Lilly
Leading Indigenous Manufacturers
- Ranbaxy Laboratories
- Cipla
- Dr Reddy’s Laboratories
- Aurobindo Pharmaceutical
- Venus Remedies
- Granules India
- Nicholas Piramal India
- Zydus Cadila
- Dishman Pharmaceuticals and Chemicals
BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Sources 0
- Pfizer
- GlaxoSmithKline (GSK)
- Novartis
- Sanofi-Aventis
- Merck & Co
- Eili Lilly
- Ranbaxy Laboratories
- Cipla
- Dr Reddy’s Laboratories
- Aurobindo Pharmaceutical
- Venus Remedies
- Granules India
- Nicholas Piramal India
- Zydus Cadila
- Dishman Pharmaceuticals and Chemicals
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
